immune repertoire sequencing
Adaptive Biotechnologies Lays out Strategy to Drive ClonoSeq Adoption
The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.
Adaptive Bio Narrows 2022 Revenue Guidance, Outlines Financial Expectations
Releasing Q3 results, the Seattle-based immune system biotechnologies firm set its new full-year revenue guidance to the range of $185 million to $190 million.
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
Adaptive Biotech's ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma
The firm's assay is the first and only test to gain coverage for this patient population, for whom ctDNA MRD assessment can help personalize treatment.
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.